Glycine - QuantitativeCSF

Glycine - QuantitativeCSF is a specialized diagnostic biochemical test designed to measure the concentration of glycine in cerebrospinal fluid (CSF). Glycine acts as a major inhibitory neurotransmitter in the central nervous system and an excitatory co-agonist at NMDA receptors. Measuring CSF glycine levels is essential for evaluating neurological disorders, central nervous system neurotransmitter imbalances, and inherited metabolic conditions such as non-ketotic hyperglycinemia (NKH).

Measurement of cerebrospinal fluid amino acids provides direct clinical insight into central nervous system metabolism and neurotransmitter regulation. Because early identification of metabolic encephalopathies supports timely therapeutic and genetic intervention, specialized biochemical testing supplies essential clinical data for neurology, pediatric neurology, genetics, and internal medicine evaluations.

The test requires a cerebrospinal fluid specimen collected by a qualified physician using a lumbar puncture procedure into standard sterile containers, followed by precise analysis using advanced laboratory chromatography or mass spectrometry techniques. Results must always be interpreted in conjunction with the patient's clinical presentation, plasma amino acid levels, and concurrent neurological assessments.

Benefits of Glycine - QuantitativeCSF Testing

• Provides a precise quantitative measurement of glycine levels in cerebrospinal fluid.
• Helps diagnose non-ketotic hyperglycinemia and central nervous system metabolic disorders.
• Assists clinicians in neurology and pediatric neurology evaluations.
• Aids in assessing inhibitory neurotransmitter function and NMDA receptor pathways.
• Supports tracking of specialized neurological and genetic care plans.
• Complements plasma amino acid profiles, CSF protein panels, and electroencephalograms (EEGs).
• Utilizes precise laboratory chromatography techniques for reliable results.
• Assists specialists in determining appropriate medical and genetic management strategies.
• Provides dependable turnaround times to support specialized clinical care.
• Utilizes standard lumbar puncture specimen collection procedures.

Clinical Indications and Applications

Neurological Screening: The primary clinical indication is evaluating neonates or patients presenting with severe encephalopathy, seizures, hypotonia, or suspected non-ketotic hyperglycinemia.

Clinical Assessment: The test is utilized when screening for central nervous system amino acid abnormalities in specialized clinical settings.

Why Doctors Recommend This Test

Neurologists, pediatric neurologists, geneticists, and metabolic specialists recommend this test when investigating complex central nervous system disorders or unexplained neonatal encephalopathy. It delivers essential quantitative data required to guide safe clinical intervention.

Following proper lumbar puncture and specimen collection guidelines will ensure a smooth and efficient testing procedure.

What Happens During The Procedure?

The collection procedure involves obtaining a cerebrospinal fluid specimen via a lumbar puncture (spinal tap) performed by a qualified medical professional using sterile collection containers under strict aseptic and clinical supervision protocols.

Once obtained, the sample is tested in the laboratory using advanced analyzers to quantify CSF glycine concentrations. The procedure requires specialized clinical monitoring.

Normal Reporting Time

The report for the Glycine - QuantitativeCSF test is generally available within 24 to 48 hours due to standard laboratory processing times. Results must be reviewed promptly with the referring neurologist or specialist.

Who Should Consider This Test?

• Neonates or infants evaluated for non-ketotic hyperglycinemia or severe seizures.
• Individuals investigated for central nervous system amino acid disorders as directed by a clinician.

Understanding Test Results

Test results provide quantitative concentrations of glycine in the cerebrospinal fluid, evaluated against established laboratory reference ranges.

Normal Findings: Normal CSF glycine levels indicate balanced neurotransmitter regulation and typical central nervous system amino acid metabolism.

Abnormal Findings: Significantly elevated CSF glycine levels, especially when compared to plasma levels, strongly suggest non-ketotic hyperglycinemia or related metabolic defects.

Clinical Limitations

CSF glycine results must be interpreted alongside simultaneous plasma amino acid levels and the patient's overall clinical history.

Important Safety Information

Severe neurological symptoms, acute seizures, or signs of encephalopathy require immediate emergency medical attention. Patients must consult their healthcare provider or specialist to interpret cerebrospinal fluid findings.